Celebrex With Preoperative Chemoradiation - Rectal Cancer
Colorectal Neoplasms
About this trial
This is an interventional treatment trial for Colorectal Neoplasms
Eligibility Criteria
Inclusion Criteria: patients with resectable or potentially resectable adenocarcinoma of the rectum clinical stage T2 N1-2 or T3-4 N0-2 (patients who require diverting loop colostomy are eligible) age greater than 18 years, ECOG performance status < 2 (appendix, section 13.1) biopsy proven adenocarcinoma, superior margin of the tumour within 15cm of the anal verge on rigid sigmoidoscopy Exclusion Criteria: Distant metastasis, Prior pelvic irradiation, Inflammatory bowel disease, Medical conditions which preclude radical therapy History of malignancy within five years (except nonmelanoma skin cancer, CIN cervix) Pregnancy Hypersensitivity to celecoxib, NSAID, sulfonamides or 5-FU Significant comorbid illness History of peptic ulcer disease or NSAID-related gastrointestinal bleeding Use of aspirin, other NSAID or coxib in the two weeks prior to study entry Neutrophil count <1.5x109/L, platelet count <100x109/L, serum bilirubin >1.25xULN (upper limit of normal), AST/ALT >3xULN, serum creatinine >1.25xULN
Sites / Locations
- Princess Margaret Hospital